In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer...read more
Metagenomi, a preclinical biotech using metagenomics-derived genome editing, raised $94 million by offering 6.3 million shares at $15, the low end of the range of $15 to $17. Metagenomi is a precision genetic medicines company developing curative therapeutics...read more
Metagenomi, a preclinical biotech developing therapies using metagenomics-derived genome editing, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17....read more
Renaissance Capital's February IPO Market Update
In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer...read more
US IPO Weekly Recap: Autoimmune biotech Kyverna Therapeutics gains 37% in a 6 IPO week
Six IPOs priced this past week, joined by two blank check companies. One larger deal did not get done: Fortegra (TFG) ...read more
Gene editing biotech Metagenomi prices IPO at $15, the low end of the range
Metagenomi, a preclinical biotech using metagenomics-derived genome editing, raised $94 million by offering 6.3 million shares at $15, the low end of the range of $15 to $17. Metagenomi is a precision genetic medicines company developing curative therapeutics...read more
Gene editing biotech Metagenomi sets terms for $100 million IPO
Metagenomi, a preclinical biotech developing therapies using metagenomics-derived genome editing, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17....read more